On May 9, 2025, Barclays analyst Gena Wang provided an update on the stock rating for 4D Molecular Therapeutics (FDMT, Financial). The rating has been maintained at "Overweight," reflecting the analyst's positive outlook on the company.
However, the price target for FDMT has been adjusted downwards. The current price target is now set at 38.00 USD, a reduction from the previous 45.00 USD. This change represents a decrease of approximately 15.56% in the projected price.
Investors may want to note these updates as they continue to monitor the performance of 4D Molecular Therapeutics (FDMT, Financial) on the NASDAQ exchange.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 10 analysts, the average target price for 4D Molecular Therapeutics Inc (FDMT, Financial) is $28.50 with a high estimate of $44.00 and a low estimate of $6.00. The average target implies an upside of 779.63% from the current price of $3.24. More detailed estimate data can be found on the 4D Molecular Therapeutics Inc (FDMT) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, 4D Molecular Therapeutics Inc's (FDMT, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for 4D Molecular Therapeutics Inc (FDMT, Financial) in one year is $0.05, suggesting a downside of 98.46% from the current price of $3.24. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the 4D Molecular Therapeutics Inc (FDMT) Summary page.
